News
-
-
PRESS RELEASE
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, the first and only multiple sclerosis biosimilar, offering cost-effective treatment. TYRUKO® approved for all indications of reference medicine Tysabri® -
-
-
-
-
PRESS RELEASE
Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio -
-
-
PRESS RELEASE
2025 Illuminations of the Champs-Elysées - JCDecaux supports Swarovski in its partnership with the Comité Champs-Elysées
JCDecaux supports Swarovski in partnership with Comité Champs-Elysées for 2025 Illuminations of the Champs-Elysées in Paris, featuring Léa Seydoux as godmother and a new 'sound and light' experience